Herantis Pharma Plcpress release, August 7, 2022 on 09:00 AM EEST
Herantis Pharma Plc (“Herantis“)which develops disease-modifying therapies for Parkinson’s disease, announced today that VD Antti Vuolanto and CFO Tone Kvåle will present and hold 1×1 meetings at Nordic Life Science Days (NLS) in Malmö, Sweden on 28-29 September 2022. Nordic Life Science Days is the largest Nordic partner conference dedicated to the life science industry.
Presentation time:
September 28, 11:12 AM EEST / 10:12 AM CEST
The presentations will only be available to attendees of the event. If you are interested in scheduling a 1×1 meeting with Heranti’s management, you can contact the conference organizers, contact us via the Nordic Life Science Days 1×1 platform and/or send an email to [email protected].
For more information please contact:
Julie Silber/Gabriela Urquilla
Phone: +46 (0)7 93 486 277/+46 (0)72-396 72 19
Email: [email protected]
Certified Counselor: UB Securities Ltd, Finland: +358 9 25 380 225, Sweden: +358 40 5161400
Company website: www.herantis.com
About Herantis Pharma Plc
Herantis Pharma Plc is an innovative biotechnology company developing disease-modifying therapies for Parkinson’s disease. Heranti’s lead product HER-096, is an advanced small and synthetic chemical peptidomimetic molecule developed based on the active site of the parent CDNF protein. It combines the compelling mechanism of action of the CDNF protein with the convenience of subcutaneous administration.
Heranti’s shares are listed on Nasdaq First North Growth Market Finland and Nasdaq First North Growth Market Sweden.
For more information, visit https://www.herantis.com
https://news.cision.com/herantis-pharma-oyj/r/herantis-pharma-to-participate-in-the-nordic-life-science-days–sweden,c3627059
https://mb.cision.com/Main/18884/3627059/1623955.pdf
(c) 2022 Severance. All rights reserved., source Press releases – English